Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma
Journal of Clinical Oncology2019Vol. 37(24), pp. 2105–2119
Citations Over TimeTop 1% of 2019 papers
John K. Lin, Lori Muffly, Michael A. Spinner, James I. Barnes, Douglas K Owens, Jeremy D. Goldhaber‐Fiebert
Abstract
At 2018 prices, it is possible that both CAR-T therapies meet a less than $150,000/QALY threshold. This depends on long-term outcomes compared with chemoimmunotherapy and stem-cell transplantation, which are uncertain. Widespread adoption would substantially increase non-Hodgkin lymphoma health care costs. Price reductions or payment for initial response would improve cost effectiveness, even with modest long-term outcomes.
Related Papers
- → Rotator cuff repair: An analysis of utility scores and cost-effectiveness(2007)255 cited
- → Cost effectiveness of population screening vs. no screening for cardiovascular disease: the Danish Cardiovascular Screening trial (DANCAVAS)(2022)22 cited
- → Cost-Effectiveness of Computer-Tailored Smoking Cessation Advice in Primary Care: A Randomized Trial (ESCAPE)(2013)20 cited
- → The comparative effectiveness and cost-effectiveness of vitreoretinal interventions(2008)21 cited
- → Preference-based comparative effectiveness and cost–effectiveness(2012)15 cited